Table 1 Immunotherapy (αPD1 and αCTLA4) response probability based on logistic regression models of tumor mutational burden (TMB), neoepitope burden (Neoepitopes), and combined tumor DNA- and RNA- variant burden (TVB) for melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). P values are reported on a per-model basis without correction for multiple comparisons per cancer type

From: Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival